Nautilus Biotechnology (NAUT) Other Non-Current Assets (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Other Non-Current Assets of $1.2 million for Q2 2026, little changed sequentially from $1.2 million in Q1 2026, and little changed YoY from $1.2 million in Q2 2025.
Nautilus Biotechnology (NAUT) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Other Non-Current Assets for 7 years, with the latest figure at $1.2 million in Q2 2026.
- Quarterly Other Non-Current Assets changed 0.25% year-over-year to $1.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.2 million (changed 0.25% YoY) and the FY2025 annual result came in at $1.2 million, changed 0.0% from the prior year.
- Other Non-Current Assets held at $1.2 million in Q2 2026 per NAUT's latest filing, from $1.2 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.8 million in Q2 2023 and troughed at $997000.0 in Q1 2022.
- A 5-year average of $1.2 million and a median of $1.2 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets soared 77.43% in 2023, then sank 33.3% in 2024.
- Over 5 years, Other Non-Current Assets stood at $1.1 million in 2022, then advanced by 6.5% to $1.2 million in 2023, then changed by 0.0% to $1.2 million in 2024, then changed by 0.0% to $1.2 million in 2025, then slipped by 0.25% to $1.2 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.2 million, $1.2 million, and $1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Mar 31, 2026 | 1.18 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 1.18 Mn |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.18 Mn |
| Mar 31, 2024 | 1.18 Mn |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | 1.16 Mn |
| Jun 30, 2023 | 1.77 Mn |
| Mar 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 1.11 Mn |
| Sep 30, 2022 | 997,000.00 |
| Jun 30, 2022 | 997,000.00 |
| Mar 31, 2022 | 997,000.00 |
| Dec 31, 2021 | 997,000.00 |
| Sep 30, 2021 | 767,000.00 |